Landscape Capital Management L.L.C. Invests $362,000 in TELA Bio, Inc. (NASDAQ:TELA)

Landscape Capital Management L.L.C. purchased a new stake in shares of TELA Bio, Inc. (NASDAQ:TELA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 143,199 shares of the company’s stock, valued at approximately $362,000. Landscape Capital Management L.L.C. owned about 0.58% of TELA Bio as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in TELA. Point72 DIFC Ltd acquired a new stake in shares of TELA Bio during the second quarter worth approximately $25,000. Embree Financial Group acquired a new stake in TELA Bio during the 3rd quarter valued at $25,000. Ground Swell Capital LLC bought a new position in TELA Bio in the 2nd quarter valued at $53,000. Point72 Asia Singapore Pte. Ltd. bought a new position in TELA Bio in the 2nd quarter valued at $115,000. Finally, Los Angeles Capital Management LLC acquired a new position in TELA Bio in the second quarter worth $131,000. 94.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TELA shares. Piper Sandler cut their price target on TELA Bio from $8.00 to $5.00 and set an “overweight” rating for the company in a report on Friday, November 8th. JMP Securities reduced their target price on shares of TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $12.00 price target on shares of TELA Bio in a report on Friday, October 4th. Finally, Lake Street Capital reduced their price objective on TELA Bio from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th.

TELA Bio Stock Performance

TELA Bio stock opened at $3.01 on Monday. The company has a market cap of $118.56 million, a PE ratio of -1.78 and a beta of 0.97. The company has a current ratio of 2.62, a quick ratio of 1.81 and a debt-to-equity ratio of 14.22. TELA Bio, Inc. has a 1 year low of $2.30 and a 1 year high of $7.84. The company’s 50-day moving average is $2.70 and its two-hundred day moving average is $3.87.

TELA Bio (NASDAQ:TELA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). TELA Bio had a negative return on equity of 556.18% and a negative net margin of 60.49%. The business had revenue of $18.96 million for the quarter, compared to the consensus estimate of $19.10 million. During the same period last year, the firm earned ($0.45) earnings per share. Equities analysts anticipate that TELA Bio, Inc. will post -1.37 earnings per share for the current year.

Insider Activity

In other news, CTO Paul Talmo bought 22,222 shares of the stock in a transaction on Thursday, October 24th. The stock was purchased at an average price of $2.25 per share, with a total value of $49,999.50. Following the completion of the purchase, the chief technology officer now owns 91,082 shares of the company’s stock, valued at approximately $204,934.50. This trade represents a 32.27 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Antony Koblish acquired 88,888 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $199,998.00. Following the purchase, the chief executive officer now directly owns 458,897 shares in the company, valued at $1,032,518.25. This trade represents a 24.02 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 182,220 shares of company stock valued at $409,995 in the last 90 days. 6.00% of the stock is owned by company insiders.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.